checkAd

     162  0 Kommentare AnaptysBio Announces Orphan Drug Designation of Imsidolimab For Treatment of Generalized Pustular Psoriasis - Seite 3

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from our clinical trials, including imsidolimab’s Phase 2 clinical trials in GPP and PPP, the timing of a regulatory strategy update for GPP and the timing of initiation of clinical trials in additional indications with imsidolimab. Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company’s ability to fund development activities and achieve development goals, the company’s ability to protect intellectual property and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

    Lesen Sie auch

    Contact:
    Eric Loumeau
    AnaptysBio, Inc.
    858.732.0179
    eloumeau@anaptysbio.com


    Seite 3 von 3




    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    AnaptysBio Announces Orphan Drug Designation of Imsidolimab For Treatment of Generalized Pustular Psoriasis - Seite 3 Additional Data and Regulatory Strategy Update From Generalized Pustular Psoriasis (GPP) Phase 2 GALLOP Trial Anticipated During H2 2020Palmoplantar pustulosis (PPP) Phase 2 POPLAR Trial Top-Line Data Anticipated in H2 2020Company Plans To Expand …